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Abstract  
Background: Preclinical studies have reported that a single treadmill session performed 24 h 
prior to doxorubicin provides cardio-protection. We aimed to characterize the acute change in 
cardiac function following an initial doxorubicin treatment in humans and determine whether an 
exercise session performed 24 h prior to treatment changes this response. Methods: Breast cancer 
patients were randomized to either 30 minutes of vigorous-intensity exercise 24 h prior to the 
first doxorubicin treatment (n=13), or no vigorous exercise for 72 h prior to treatment (control, 
n=11). Echocardiographically-derived left ventricular volumes, longitudinal strain, twist, E/A 
ratio, and circulating NT-proBNP, a marker of later cardiotoxicity, were measured before and 
24-48 h after the treatment. Results: Following treatment in the control group, NT-proBNP, end-
diastolic and stroke volumes, cardiac output, E/A ratio, strain, diastolic strain rate, twist, and 
untwist velocity significantly increased (all p≤0.01). Whereas systemic vascular resistance 
(p<0.01) decreased, and ejection fraction (p=0.02) and systolic strain rate (p<0.01) increased in 
the exercise group only. Relative to control, the exercise group had a significantly lower NT-
proBNP (p<0.01) and a 46% risk reduction of exceeding the cut-point used to exclude acute 
heart failure. Conclusion: The first doxorubicin treatment is associated with acutely increased 
NT-proBNP, echocardiographic parameters of myocardial relaxation, left ventricular volume 
overload, and changes in longitudinal strain and twist opposite in direction to documented 
longer-term changes. An exercise session performed 24 h prior to treatment attenuated NT-
proBNP release and increased systolic function. Future investigations should verify these 
findings in a larger cohort and across multiple courses of doxorubicin.  
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1 Introduction 
 The anthracycline chemotherapy agents doxorubicin and epirubicin are a cornerstone for 
treatment of early and advanced breast cancer, but are unfortunately associated with a dose-
dependent cardiotoxicity [1]. Anthracycline-related cardiotoxicity is theorized to begin with an 
acute subclinical cardiac injury [1], as evidenced by changes in endomyocardial biopsy 
morphologic grade, elevation of circulating cardiac troponins or natriuretic peptides, and 
impairments in left ventricular (LV) longitudinal strain occurring early in treatment [2-4]. When 
this acute injury occurs repeatedly, as with multiple treatments, or in the presence of other risk 
factors (e.g. advanced age, diabetes), it may result in adverse LV remodeling [1]. Despite this 
evidence for cardiac injury early in the course of treatment, acute changes in cardiac function 
following the first anthracycline treatment have not been evaluated. 
 Cardio-protective strategies that mitigate myocardial damage early during treatment may 
aid in preventing long-term cardiotoxicity. Oxidative stress and the related apoptosis of 
cardiomyocyte mitochondria are primary mechanisms of anthracycline-induced cardiotoxicity 
[5]. Due to its role in improving myocardial tolerance to oxidative stress, exercise is a potentially 
attractive non-pharmacological strategy for the prevention of anthracycline-related myocardial 
injury [5]. Previously, a 60-minute moderate-to-vigorous intensity bout of aerobic exercise has 
been shown to protect the myocardium in preclinical models of acute myocardial insult, and has 
recently been shown to either completely prevent or significantly attenuate anthracycline-related 
systolic and diastolic dysfunction, cardiomyocyte mitochondrial dysfunction and apoptosis in 
rodents [5,6]. Whether these results can be translated into humans receiving anthracycline 
treatment is not known.   
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 The aims of this study are to characterize the acute changes in cardiac function following 
the first doxorubicin treatment; and to determine whether a single exercise session performed 24 
h prior to the treatment modifies cardiac function in women with early stage breast cancer. It was 
hypothesized that the exercise session would attenuate acute changes in circulating and 
echocardiographic markers of cardiotoxicity. 
2 Methods 
2.1 Design and ethical approval 
This study was a two-arm proof-of-concept randomized controlled trial, where breast 
cancer patients were randomly allocated to perform either a single supervised exercise session or 
no exercise prior to the first chemotherapy treatment. A permutated block design, with random 
block sizes of four and six, and stratification by age ≥50/<50 years was used with a 1:1 allocation 
ratio generated by a spreadsheet random function by someone not involved in the study, and 
implemented with sequentially numbered envelops. The first author performed study enrollment 
and participant assignment. This study complies with the Declaration of Helsinki and was 
approved by the Clinical Research Ethics Board of the University of British Columbia. All 
participants provided written informed consent.  
2.2 Participants 
 Participants were recruited through oncologist referral and posters. Women aged 18+ 
years with stage I - III breast cancer that were scheduled to receive neoadjuvant or adjuvant 
doxorubicin-containing chemotherapy were eligible. Participants had to agree to accept random 
allocation to either group, be able to complete the baseline assessment prior to their first 
doxorubicin treatment, and speak English, Cantonese, or Mandarin. Exclusion criteria included 
concurrent enrollment in an exercise training or pharmacological cardio-protection trial, current 
smoker, orthopedic limitations to exercise, a body mass index (BMI) >35 kg/m2, pre-existing 
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cardiovascular disease, or previous receipt of anthracyclines, trastuzumab, or thoracic 
radiotherapy. Participants reporting a history of hypertension, diabetes, or lung disease were 
included if they reported that the condition was well controlled by medication over the previous 
year. The Physical Activity Readiness Questionnaire (Canadian Society of Exercise Physiology) 
was also administered for screening.   
2.3 Intervention 
 The exercise group (EX) performed a single bout of supervised treadmill exercise ending 
approximately 24 h prior to the participant’s treatment time. The session consisted of a 10-
minute warm-up, 30 minutes at 70% of age-predicted heart rate (HR) reserve ([(206–0.88 * 
age)–resting HR] * 0.7 + resting HR), which corresponds to a vigorous intensity, and a 5-minute 
cool-down. Resting HR used in the calculation was measured immediately prior to the exercise 
session following five minutes of quiet, seated rest.   
 Participants in both EX and the control group (CON) were asked to abstain from vigorous 
intensity exercise (described as “rapid heart beating, sweating a fair amount, and breathing 
hard.”) for 72 h prior to, and 48 h after the treatment. All participants were free to perform light 
or moderate intensity exercise at any time in agreement with current guidelines for cancer 
survivors.[7] Prior to exercise sessions and assessments, participants were asked to refrain from 
caffeine, alcohol and non-vital drugs for 3 h, and food for at least 1 h.  
2.4 Outcome measures   
 All measures were performed within a research setting 0-14 days before the first 
doxorubicin treatment (baseline) and 24-48 h after the scheduled start time of each participant’s 
first doxorubicin treatment (acute follow-up).  
2.4.1 Cardiac biomarkers  
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 The amino terminal of B-type natriuretic peptide (NT-proBNP) was chosen as the 
primary outcome as it is consistently reported to have a response at 24 h after the first 
anthracycline treatment [8,9]. NT-proBNP and cardiac Troponin T (cTnT) levels were measured 
by the proBNP II and Troponin T high sensitive short turnaround time and 
electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Laval, Quebec). All 
biomarker levels were compared to normal reference ranges. For NT-proBNP, the commonly 
used cut-point to exclude acute heart failure of 300 pg/mL was used, along with age-related cut-
points used to identify acute heart failure of 450 pg/mL for <50 years or 900 pg/mL for 50-75 
years [10]. For high sensitive cTnT, the 99th percentile of normal for females (8 pg/mL) was used 
as the cut-point [11]. 
2.4.2 Cardiac function 
 Two-dimensional transthoracic echocardiograms (Vivid i Ultrasound, 3S-RS cardiac 
probe, GE Healthcare, Mississauga, ON) were performed in the left lateral decubitus position 
according to current guidelines [12] by a certified cardiac sonographer who was blinded to group. 
A frame rate of 80 fps was used for all images and ultrasound settings were standardized within 
each participant. LV volumes and ejection fraction (LVEF) were assessed using the modified 
Simpson’s Biplane method. Speckle-tracking was used to assess longitudinal strain and strain 
rate (SR) from the apical 4-chamber image. LV twist was determined as the peak difference 
between basal rotation and apical rotation measured in the short axis at the level of the mitral 
leaflets, and the level proximal to luminal obliteration, respectively.  
  HR was measured from the ultrasound’s electrocardiogram concurrent to the apical 4-
chamber image acquisition. Resting blood pressure was measured following the echocardiogram 
(after ~20 minutes of rest) using manual auscultation as the average of two measurements 
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performed 60 s apart. Systemic vascular resistance (SVR) was calculated as: 80 * (mean arterial 
pressure / cardiac output).    
 A single trained investigator performed all echocardiography analyses blinded on 
Echopac Version 112 (GE Healthcare, Mississauga, ON). All values were averaged over three 
cardiac cycles. For the strain analysis, segments without adequate tracking (as assessed by visual 
inspection) were excluded; at least four segments were required. Custom-made software (2D 
Strain Analysis Tool, Stuttgart, Germany) was used to adjust for intra and inter-individual 
variability of HR by normalizing to the percentage of systolic and diastolic duration via cubic 
spline interpolation [13]. Our test-retest (1-5 days) difference and coefficient of variation for this 
population for key measurements are: 2.1±1.2 and 2.6±1.4% for LVEF, 1.3±0.6 and 5.0±2.6% 
for longitudinal strain.   
2.4.3 Descriptive variables  
 A brief questionnaire was used to collect self-reported demographic, diagnosis, treatment, 
medication and medical history data. Clinical blood assessments were extracted from patient 
records. The Godin Leisure Time Exercise Questionnaire [14] quantified moderate-to-vigorous 
intensity aerobic physical activity (MVPA) for the seven days before and after the first treatment.  
2.5 Statistical analyses 
 Baseline characteristics and physical activity were compared using two-tailed 
independent t-tests or Mann-Whitney U tests as appropriate. The other physical variables were 
analyzed with a generalized estimating equation in SPSS Version 24.0 (IBM Corporation, NY). 
The Quasi Likelihood under Independence Model Criterion, and the corrected version of this 
criterion were respectively used to choose the best fitting model type (i.e. distribution and link 
function) and working correlation matrix for each variable. Hypothesized differences were 
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investigated for significant group by time interactions using contrasts (i.e. baseline versus 
follow-up for each group, and follow-up between groups). However, it is recommended that a 
non-significant interaction should not preclude pairwise comparisons when there is biological 
relevance of a potential difference between treatment and control groups [15]. As a compromise 
to minimize multiple comparisons but not miss potential real effects in this proof-of-principle 
study, contrasts were performed on non-significant interactions for variables that potentially 
explain significant findings. The relative risk of the biomarkers exceeding the reference ranges at 
follow-up was calculated for each group. The p≤0.05 level was considered significant and 
adjustments were not made for multiple comparisons.    
 In the preclinical versions of this study, the effects of exercise on invasive measures of 
cardiac function were estimated using available data as having a medium effect size (cohen’s 
d≈0.50). Twenty-four participants total provided 80% power with our repeated measures within-
between interaction design to detect a medium (cohen’s f=0.30) effect size (G*Power 3.0.10; 
Düsseldorf, Germany).  
3 Results 
3.1 Recruitment and participants 
 Twenty-seven participants enrolled in the study between June 2013 and March 2016; one 
from each group withdrew, and another in CON became ineligible after her treatment protocol 
was changed to no longer include anthracyclines; leaving n=13 in EX and n=11 in CON who 
completed the study (Fig 1). The baseline data of the withdrawal was not carried forward to 
follow-up on the basis that chemotherapy is expected to change the outcome measures. One 
participant in CON was not willing to have the follow-up echocardiogram, but completed all 
other measures; all completed data were included. The acute follow-up was performed 25.5±5.4 
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and 30.1±8.1 h after treatment for EX and CON respectively (p=0.14). All participants received 
60 mg/m2 of doxorubicin and 600 mg/m2 of cyclophosphamide. Five participants (2 CON, 3 EX) 
received four cycles of paclitaxel prior to this treatment. Trastuzumab treatment was not started 
until after study completion. The participant characteristics are described in Table 1. At baseline 
there were no differences between groups in body mass index (p=0.19), hemoglobin (CON, 
12.7±1.1; EX, 13.0±1.0 g/dL, p=0.53), creatinine (CON, 68±13; EX, 66±5 mol/L, p=0.33), or 
estimated glomerular filtration rate (CON, 86±20; EX, 89±13 mL/min/1.73m2, p=0.62).  
 The exercise sessions were performed an average of 23.7±1.6 h prior to treatment, for the 
prescribed duration at 71±3% of HR reserve with no adverse events. All participants reported 
abstaining from vigorous exercise for 72 h prior and 48 h after treatment as requested, and there 
were no differences in MVPA for the week before (p=0.27) or the week after (p=0.19) the first 
treatment.  
2.2 Cardiac outcomes 
 There was a significant interaction for NT-proBNP, where both groups increased 
(p<0.01), but EX’s response was significantly attenuated relative to CON (p<0.01) (Fig 2). No 
participants exceeded the biomarker cut-points at baseline. At follow-up, 1 of 13 (8%) 
participants in EX exceeded the NT-proBNP cut-point to exclude acute heart failure (300 pg/mL), 
relative to 6 of 11 (54%) in CON; a relative risk of 0.14 (95% confidence interval 0.02–1.00) and 
absolute risk reduction of 46%. No participants exceeded the NT-proBNP cut-points for 
identifying acute heart failure. The interaction or change over time was not significant for cTnT 
(Table 2), and no participants exceeded the clinical cut-point. 
Based on the role that LV load plays in the secretion of NT-proBNP,[3] blood pressure 
and LV volumes were compared within each group over time and between groups at the follow-
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up despite non-significant interactions. There was no change or difference in systolic blood 
pressure, yet there was a significant decrease in SVR (p<0.01), diastolic (p<0.01), mean arterial 
(p=0.03), and pulse (p=0.05) pressures in EX only (Table 2). Pulse pressure was significantly 
higher in EX relative to CON at follow-up (p=0.02). There was a significant increase in end-
diastolic volume in CON (p<0.01) only. While CON appeared to have a small increase, and EX a 
small decrease in end-systolic volume, these changes were not statistically significant. Stroke 
volume (p<0.01) increased significantly in both groups with no differences (Table 2). LVEF was 
increased in EX only (p=0.02).  
There was no significant interaction for HR, cardiac output or E/A ratio, yet there was a 
significant increase with time for cardiac output and E/A ratio (p≤0.01). 
While there was no significant interaction for strain or twist, the contrasts were explored 
given the differential change in end-diastolic volume, and the known preload effect on these 
variables [16,17]. The increase in strain was significant for both groups (p<0.01), with no 
difference between groups, while the increase in twist was significant for CON only (p=0.02). 
There was a significant interaction for systolic SR, where it increased in EX only (p<0.01). There 
were no significant interactions for early diastolic SR, twist or untwist velocity, but early 
diastolic SR and untwist increased with time (p≤0.01). 
4 Discussion  
 This is the first study to characterize the acute change in cardiac function following the 
first doxorubicin treatment for breast cancer, and to show that a single session of exercise 
performed 24 h prior to treatment can attenuate the acute release of NT-proBNP and reduce the 
absolute risk of exceeding the cut-point excluding acute heart failure after the first doxorubicin 
treatment by 46%.  
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4.1 The acute change in cardiac function following the first doxorubicin treatment 
 Natriuretic peptides, including NT-proBNP, play a key role in the homeostasis of cardiac 
pressure and volume [18]. Elevated NT-proBNP in the context of cardiotoxic cancer therapy may 
reflect pathologic volume overload [3], as higher B-type natriuretic peptide levels during 
treatment with anthracycline treatment are predictive of development of heart failure, death, and 
cardiac events [18]. Relevant to the current study, among breast cancer patients being treated 
with anthracyclines, an NT-proBNP elevation after one treatment, as well as persistent elevations 
after multiple treatments, are associated with a significant reduction in LVEF over time [8,9]. 
Although no participant’s NT-proBNP levels exceeded the age-related cut-points for identifying 
acute heart failure, it is likely clinically relevant that acute heart failure could not be excluded for 
54% of CON participants following their first of four doxorubicin treatments. This is especially 
concerning given these participants’ prior healthy cardiovascular status. 
 NT-proBNP is synthesized and secreted by the myocardium in response to increased 
hemodynamic stress including increased LV end-diastolic volume and pressure [18]. Indeed, in 
the current study, end-diastolic volume increased with no change in blood pressure in CON, 
which may be the cause of the increased NT-proBNP secretion. NT-proBNP elevations can 
enhance myocardial relaxation [19], which is demonstrated in both groups by the increased 
diastolic SR, untwist velocity, and E/A ratio. While these changes may be in line with expected 
physiological mechanisms and consequences of NT-proBNP synthesis and secretion, given that 
greater NT-proBNP release after anthracycline treatment has been associated with later LVEF 
deterioration [8,9], these changes could be potential targets for cardio-protection.  
 Similar to previous studies [9], cTnT did not increase significantly following the first 
doxorubicin treatment perhaps due to variable timing in release kinetics between individuals [3], 
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or that the cardiac stress detected by NT-proBNP occurs earlier than the cardiomyocyte necrosis 
that may be detected by cTnT [20].  
 The significant increase in longitudinal strain and twist from pre-chemotherapy to 24 - 48 
h after the first treatment was unexpected. In children and rodents, strain and SR have been 
reported to deteriorate from pre-treatment by 2 and 24 h after the first anthracycline treatment 
[21,22]. No studies of adults being treated with anthracyclines have measured strain earlier than 
the mid-point (typically three cycles) of treatment where deterioration is consistently reported [4]. 
In terms of the potential mechanisms responsible for the acute increase in strain and twist 
observed in the present study, an increase in preload has been shown to increase longitudinal 
strain in patients referred for routine coronary angiography [16], and twist in an isolated perfused 
canine heart [17]. The cause for the increase in end-diastolic volume in the current study could 
be related to increased blood volume, but the effect of chemotherapy on blood volume is 
unknown. Dysfunction of the subendocardium leading to reduced contraction of this layer 
relative to the subepicardium may also cause an increase in twist [23]. Anthracycline-related 
morphological cardiomyocyte damage occurs intramurally, but with the highest concentration in 
the subendocardium [24]. Given that other studies have reported a decrease in twist later during 
anthracycline treatment [25], it appears that the acute increase in twist is an early compensatory 
mechanism.  Future studies could longitudinally compare acute to chronic changes in twist. 
4.2 Attenuation of the acute changes in cardiac function following the first doxorubicin by 
a single exercise session 
 Similar to the pre-clinical versions of this study, a single vigorous-intensity aerobic 
exercise session performed 24 h prior to a doxorubicin treatment attenuated some changes noted 
in CON, specifically, the increase in NT-proBNP, end-diastolic volume and twist. Several 
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mechanisms may explain the attenuation of NT-proBNP release following the exercise session: 
1) the acute exercise could have changed the physiological conditions at the time of receipt of 
doxorubicin, such as increased nitric oxide and vasodilation [26], such that less NT-proBNP 
secretion was required to maintain cardiac pressure and volume homeostasis; 2) short-term 
adaptations may have occurred in the 24 h between the exercise and chemotherapy such as 
increased antioxidants or improved cellular calcium handling [27], such that the cardiomyocytes 
were better able to tolerate the biochemical stress associated with doxorubicin; or 3) the exercise 
session increased doxorubicin pharmacokinetics and/or metabolism such that the NT-proBNP 
was either released earlier, cleared earlier, or both. Future studies should include another 
measurement immediately prior to the doxorubicin treatment in EX to examine changes in blood 
volume, vagal tone, and nitric oxide bioavailability occurring as a result of acute exercise in this 
population. 
In the current study, systolic SR was increased in EX but did not change in CON. 
Systolic SR is a better correlate of the peak positive first derivative of LV pressure (dP/dtmax), a 
surrogate of myocardial contractility, than strain [28]. Our systolic SR results were similar to the 
effect on dP/dtmax observed in the preclinical version of the current study, where the exercise 
session significantly attenuated the decrease in contractility that occurred in the CON [6]. There 
was also a small but statistically significant increase in LVEF in EX in the current study. 
Together these two findings potentially indicate an exercise-induced increase in systolic function, 
perhaps partially due to a reduced afterload, but future studies with larger sample sizes are 
required to definitively determine differences between groups. 
Interestingly, a reduction in longitudinal systolic SR with anthracycline treatment has 
been associated with increased circulating ROS, as well as a decrease in the antioxidant 
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glutathione peroxidase [29]. The primary mechanism responsible for aerobic exercise cardio-
protection is thought to be the upregulation of antioxidants and subsequent reduction in oxidative 
stress [30]. Therefore, this study may provide indirect support for this mechanism in humans. 
The exercise session also appeared have an effect on peripheral hemodynamics in the 
current study. In EX, there was a significant decrease in SVR that was proportionally larger than 
the significant reduction in mean arterial pressure, indicating that cardiac output may have been 
increased to partially counteract the vasodilation. Increased vasodilation has been reported to 
occur 12-24 h after acute exercise [26]. 
4.3 Strengths and limitations 
 The original features of this study are the measurement of cardiac function and markers 
of subclinical cardiotoxicity in the characterization of the acute change in cardiac function 
following doxorubicin treatment, and translation of an innovative cardio-protective intervention 
from animal models to human breast cancer patients via a randomized controlled design. We 
strategically recruited a homogenous population with respect to baseline health and risk factors 
to aid in signal detection in this proof-of-principal study, but this limits generalization to a wider 
breast cancer population. Another important limitation is that patients enrolled in the study with 
the expectation that they may be required to exercise. The selection bias inherent to exercise 
studies also limits the generalizability of these results to a cohort with higher baseline health. We 
attempted to control for this by stressing to both referring oncologists and potential participants 
that neither good baseline fitness nor exercise experience were required. Other limitations 
include the small sample size, multiple statistical comparisons, use of self-reported medical 
history, and lack of measurement of potentially explanatory variables including autonomic 
function, vascular function, and blood volume.  
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    In summary, there is a significant acute increase in NT-proBNP in response to the first 
doxorubicin treatment for breast cancer. Concurrent cardiac function changes included LV 
volume overload, echocardiographic markers of myocardial relaxation, and increased 
longitudinal strain and twist. The exercise session attenuated NT-proBNP, reducing the absolute 
risk of exceeding the cut-point for excluding acute heart failure by 46%, as well as other changes 
indicating vasodilation and increased systolic function. This study provides preliminary evidence 
of an accessible and feasible intervention that exerts seemingly positive effects on the cardiac 
response to doxorubicin in humans. As human patients will receive multiple treatments with 
doxorubicin, further investigations should examine the utility of this intervention when 
performed prior to each treatment to enhance the clinical relevance of this finding. A single 
aerobic exercise session performed prior to each chemotherapy cycle is a widely accessible and 
scalable intervention that would be feasible for most individuals with cancer.  
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Abbreviations list: 
BMI = body mass index 
CON = control group 
cTnT = cardiac troponin T 
EX = exercise group 
HR = heart rate 
LV = left ventricular 
MVPA = moderate-to-vigorous physical activity 
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NT-proBNP = amino terminal of B-type natriuretic peptide 
SR = strain rate 
SVR = systemic vascular resistance 
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Table 1: Baseline participant characteristics 
 Total 
n = 24 
Control 
n = 11 
Exercise 
n = 13 
Age (years) (mean±SD) 50±9 50±10 51±9  
Body mass index (kg/m2)  26.7±5.1 25.0±4.8 
Menopausal status (n (%)) 
   Pre-menopausal 
   Post-menopausal 
   Peri-menopausal 
 
8 (33%) 
10 (42%) 
6 (25%) 
 
4 (36%) 
6 (55%) 
1 (9%) 
 
4 (31%) 
4 (31%) 
5 (38%) 
Ethnicity (n (%)) 
   Caucasian 
   Asian 
   Other 
 
18 (75%) 
5 (21%) 
1 (4%) 
 
7 (64%) 
3 (27%) 
1 (9%) 
 
11 (85%) 
2 (15%) 
0 
Marital status (n (%)) 
   Married/common-law 
   Divorced/separated/widowed 
   Single 
 
16 (67%) 
3 (13%) 
5 (21%) 
 
8 (73%) 
2 (18%) 
1 (9%) 
 
8 (62%) 
1 (8%) 
4 (31%) 
Education (n (%)) 
   Bachelor’s degree or above 
   Below Bachelor’s degree 
 
15 (63%) 
9 (37%) 
 
5 (45%) 
6 (55%) 
 
10 (77%) 
3 (23%) 
Comorbid conditions (n (%)) 
  Angina 
   Diabetes 
   Asthma 
   Arthritis 
   Hypertension 
   Dyslipidemia 
 
1 (4%) 
1 (4%) 
4 (17%) 
4 (17%) 
2 (8%) 
0 
 
0 
1 (9%) 
2 (18%) 
0 
1 (9%) 
0 
 
1 (8%) 
0 
2 (15%) 
4 (31%) 
1 (8%) 
0 
Medications (n (%)) 
   Thyroid replacement 
   Statin 
   Calcium channel blocker 
   Beta-blocker 
   Metformin 
 
4 (17%) 
3 (13%) 
1 (4%) 
1 (4%) 
1 (4%) 
 
1 (9%) 
1 (9%) 
0 
1 (9%) 
1 (9%) 
 
3 (23%) 
2 (15%) 
1 (8%) 
0 
0 
   ACE-inhibitor 0 0 0 
   Angiotensin receptor blocker 0 0 0 
Stage (n (%)) 
   I 
   II 
   III 
 
4 (17%) 
12 (50%) 
8 (33%) 
 
3 (27%) 
5 (45%) 
3 (27%) 
 
1 (8%) 
7 (54%) 
5 (38%) 
Surgery (n (%)) 
   Lumpectomy 
   Mastectomy 
 
10 (42%) 
6 (25%) 
 
4 (36%) 
3 (27%) 
 
6 (46%) 
3 (23%) 
   None (neoadjuvant therapy) 8 (33%) 4 (36%) 4 (31%) 
Abbreviations: ACE = angiotensin-converting enzyme; n = sample size; SD = standard deviation 
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Table 2:  Hemodynamic, left ventricular function, and biomarker data  
Parameter Group Baseline 
Acute follow-
up 
Interaction 
p-value 
Time p-
value 
Circulating cardiac biomarker  mean±SD mean±SD   
NT-proBNP (pg/mL) Control 59±35 323±151† 0.01  
 Exercise 52±30 214±77†‡   
Cardiac troponin T (pg/mL) Control 1.5±2.3 1.9±2.6 0.97 0.23 
 Exercise 1.3±2.1 2.6±3.2   
Hemodynamics      
Heart rate (bpm) Control 69±12 67±13 0.08 0.79 
Exercise 69±11 72±14   
Systolic blood pressure 
(mmHg) 
Control 102±12 98±17 0.82 0.23 
Exercise 102±12 100±10   
Diastolic blood pressure 
(mmHg) 
Control 63±12 61±11 0.19 0.01* 
Exercise 62±10 55±8†   
Pulse pressure (mmHg) Control 38±8 37±7 0.10 0.27 
Exercise 39±8 44±4†‡   
Mean arterial blood pressure 
(mmHg) 
Control 76±11 74±13 0.43 0.03* 
Exercise 75±10 70±8†   
Systemic vascular resistance 
(dynes·sec·cm-5) 
Control 2074±514 1805±503 0.43 <0.01* 
Exercise 1933±445 1556±473†   
LV function      
End-diastolic volume (mL) Control 77±10 87±13† 0.28 <0.01* 
 Exercise 83±17 87±13   
End-systolic volume (mL) Control 33±6 36±7 0.21 0.73 
 Exercise 36±9 34±5   
Stroke volume (mL) Control 44±6 51±8 0.47 <0.01* 
 Exercise 47±9 53±9   
Cardiac output (L/min) Control 3.0±0.5 3.4±0.7 0.55 <0.01* 
 Exercise 3.2±0.6 3.8±0.8   
LVEF (%) Control 58±3 59±4 0.40 0.03* 
 Exercise 57±4 60±3†   
E/A ratio Control 1.27±0.32 1.35±0.25 0.25 0.01* 
 Exercise 1.20±0.37 1.42±0.33   
Longitudinal strain (%) Control -19.6±1.9 -21.5±1.6 0.61 <0.01* 
Exercise -19.2±1.9 -21.4±1.8   
Systolic longitudinal strain 
rate (sec-1) 
Control -1.03±0.08 -1.06±0.09 <0.01  
Exercise -0.98±0.15 -1.15±0.20†   
Diastolic longitudinal strain 
rate (sec-1) 
Control 1.29±0.26 1.47±0.30 0.49 <0.01* 
Exercise 1.22±0.35 1.49±0.45   
Twist (°) Control 16.4±5.9 22.4±7.8† 0.50 <0.01* 
 Exercise 16.4±7.6 20.3±8.5   
Twist velocity (°·sec-1) Control 109±27 125±47 0.35 0.27 
 Exercise 121±32 124±32   
Untwist velocity (°·sec-1) Control -95±32 -133±39 0.67 0.01* 
 Exercise -95±39 -121±54   
Abbreviations: bpm = beats per minute; cm = centimeter; mL = milliliter; mmHg = millimeters of 
mercury; ms = millisecond; m/s = meters per second; sec = second; 
*Significant main effect for time at p≤0.05 
† Significantly different from baseline with pairwise contrast at p≤0.05 
‡ Significantly different from control group at same time point at p≤0.05  
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Fig 1. CONSORT flow diagram 
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Fig 2. Responses of variables that differed between the exercise and control groups. * indicates 
statistically significant change or difference at p≤0.05. Data are estimated marginal mean ± standard error. 
 
